In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026), hosted by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and organized by the National Clinical Research Center for Hematologic Diseases and the Institute of Hematology at Peking University, will be grandly held in Beijing on April 24–25, 2026.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential academic events in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry leaders to explore cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while advancing academic exchange and innovation in the field.

Immune thrombocytopenia (ITP) is a complex autoimmune disorder involving multiple immune pathways and abnormalities in platelet production. In recent years, continuous advances in drug development and evolving treatment paradigms have been reshaping the clinical landscape of ITP.

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was successfully held in Beijing. The event brought together leading scholars, clinicians, and industry experts from around the world to exchange insights on cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while shaping the future direction of the field.

Thrombotic diseases are associated with high incidence, mortality, and disability rates, posing a serious threat to public health. Venous thromboembolism (VTE), in particular, often presents insidiously, and dislodged thrombi can lead to pulmonary embolism—earning it the reputation of a “silent killer.”

At the recent EBMT 2026 Annual Meeting, Prof. Ane Altuna Mongelos from Hospital Clínic de Barcelona and IDIBAPS delivered a presentation titled "CD19/CD84 IF-BETTER dual CAR T cells demonstrate superior control of CD19-low B-ALL than single CAR19." The report explored novel pathways to overcome antigen escape in B-cell acute lymphoblastic leukemia (B-ALL) through a dual-targeting strategy.

As the landscape of hematopoietic stem cell transplantation (HSCT) continues to evolve, umbilical cord blood transplantation (CBT) maintains a critical position in the treatment of hematologic malignancies due to its unique immunological advantages. However, delayed engraftment and high non-relapse mortality (NRM) were once significant bottlenecks limiting its clinical utility. At a recent academic symposium, Professor Annalisa Ruggeri—Chair of the Cell Therapy & Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT) and Scientific Chair of Eurocord—delivered a profound presentation on "Regenerative Cord Blood Transplantation." Professor Ruggeri provided an in-depth analysis of the latest advancements, ranging from the optimization of donor selection and conditioning regimens to breakthrough ex vivo expansion technologies such as UM171. Her insights highlighted how technical innovations are overcoming traditional limitations of CBT to deliver superior survival outcomes for high-risk patients.

Severe Aplastic Anemia (SAA), as a highly heterogeneous bone marrow failure (BMF) disorder, continues to present a clinical challenge regarding the optimal choice between immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT). During the recent European Society for Blood and Marrow Transplantation (EBMT) meeting, Professor Antonio Risitano provided a comprehensive overview of the Severe Aplastic Anemia Working Party (SAAWP) core activities, landmark clinical trials, and biological discoveries. This review deconstructs the key highlights of his presentation to provide clinicians with a cutting-edge international reference for evidence-based medicine.